Dong-A Socio, Alteogen & DMBio signs contract service agreement of macular degeneration treatment

Published: 2017-09-29 14:29:43

Updated: 2017-09-29 14:29:43

Alteogen(CEO Soon-Jae Park), a company which are developing a biosimilar of macular degeneration treatment ‘Eylea,’ announced on the 28^th that it signed a Eylea biosimilar manufacturing agreement with DMBio(Byung-Jo Min, Kawasaki Yoshikuni) and Dong-A Socio Holdings(CEO Jong-Hyun Han).

Under the agreement, DMBio and Alteogen are expected to cooperate to commercialize the Eylea biosimilar ‘ALT-...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.